Conceptual illustration of C’ dot nanoparticles adapted with HER2-targeting antibody fragments (dark blue and green) and cancer-killing drugs (teal), entering a tumor cell via HER2 receptors (orange).
A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers found.
The results of the “hit and run” drug delivery system, published in the March issue of Advanced Therapeutics, were the culmination of more than five years of collaboration between Cornell, the Memorial Sloan Kettering Cancer Center (MSKCC) and biopharmaceutical company AstraZeneca.
“I’ve seen beautiful results before, but I’ve never seen something that eradicates a tumor like this,” said study co-lead author Dr. Michelle Bradbury, MSKCC director of intraoperative imaging and professor of radiology at Weill Cornell Medicine.
The other co-lead authors are Ulrich Wiesner, the Spencer T. Olin Professor in the Department of Materials Science and Engineering, at Cornell Engineering; and J. Anand Subramony, vice president of protein engineering research and development at AstraZeneca at the time of the study.
Targeted cancer treatments such as antibody and nanoparticle therapies have seen narrow clinical use because of each therapy’s limitations, but the new therapeutic – an evolution of what the researchers call Cornell prime dots, or C’ dots – combines the best attributes of both into an ultrasmall, powerfully effective system.
As silica nanoparticles just 6 nanometers in size, C’ dots are small enough to penetrate tumors and safely pass through organs once injected into the body. Wiesner first developed them more than 15 years ago and, in collaboration with Bradbury, published a 2018 study that found an antibody fragment-nanoparticle hybrid to be especially effective in finding tumors.
This collaborative work with AstraZeneca set off the search for a new, molecularly engineered therapeutic version of this immuno-conjugate.
AstraZeneca “site engineered” fragments of antibodies so they would effectively attach to the C’ dots and target HER2 proteins associated with gastric cancer. The team optimized fragment conjugation to the C’ dot surface, along with specialized inhibitor drugs developed by AstraZeneca. This enabled the nanoparticles to carry about five times more drugs than most antibodies.
The final product was a version of C’ dots, armed with cancer-targeting antibody fragments and a large drug payload, all packed into a sub-7-nanometer, drug-immune conjugate therapy – a first of its kind in that size class, according to the researchers.
“We describe the mode of action as ‘hit and run,’” Wiesner said, “because the C’ dots either target the tumor microenvironment and kill the tumor cells or get safely cleared out of the body via renal clearance as a result of their small size, thereby minimizing off-target accumulation and associated side effects and toxicity.”
Mice with gastric cancer received three doses of the therapeutic. Not only did the treatment eradicate the disease in every mouse, but there was no evidence of tumor recurrence after nearly 200 days.
“Usually you’d have to couple the treatment with other therapies to see those kind of long-term results,” Bradbury said. “It showed that the very detailed, careful work of this team – the years spent on the stoichiometry and the surface chemical developments – it paid off.”
Bradbury underscored the versatility of the C’ dots platform, and said she envisions it being used not as a replacement for antibody treatments, but as a complementary tool that can be adapted to different types of cancers and other specific needs of patients.
“C’ dots have become unusually efficacious and safe in treating cancer. They completely obliterated the tumor, even at the cellular level,” said Wiesner. “This is what we ultimately had hoped for and it further supports our earlier decision to bet on therapeutic C’ dot applications.”
Wiesner and Bradbury said the research behind the new C’ dot therapeutic will be continued by Elucida Oncology, a startup company they founded to help bring the technology to market. They said that while Elucida is not using antibody fragments in their current clinical trial of C’ dots, the work will help them build new conjugates that can potentially utilize such fragments in future trials.
Original Article: Antibody fragment-nanoparticle therapeutic eradicates cancer
The Latest Updates from Bing News
Go deeper with Bing News on:
Cornell prime dots
- Is Amazon Prime still worth it? All the pros and cons
Bad news, Amazon Prime Video members. If you haven't noticed, all Prime Video content now includes ads. If you're a Prime member and you'd like to opt out of viewing the ads, it'll cost you an ...
- Posting ‘Zionists must die’ is awful. But it shouldn't get student kicked out of college.
Maria Lima Valdez’s year has gotten off to a rocky start. Last month, the Cornell University undergrad and former Biden White House intern allegedly posted “ZIONISTS MUST DIE!” on Instagram.
- CORNELL BIG RED NEWS
Young leads Columbia to 45-22 win over Cornell in finale Ryan Young ran for two third-quarter touchdowns and Fara’ad McCombs returned a kick-off 48 yards for a score as Columbia rolled past ...
- Major Cornell donor Jon Lindseth ready for battle against woke mob at alma mater
Good news: Another major donor is taking the fight to woke at an Ivy. Jon A. Lindseth, one of Cornell’s most prominent donors, announced in an open letter to the school’s board of trustees ...
- Is Cornell Next? School’s Wealthy Donors Call for President’s Ouster
Now, a new group of donors are pulling out the same playbook at Cornell University. Jon Lindseth, a Cornell alumnus, donor and former trustee, asked the school’s Board of Trustees to dismiss ...
Go deeper with Bing News on:
- DOT: Crash shuts down portion of I-77 in Mooresville
Two out of three lanes of a portion of Interstate 77 North in Mooresville are shut down and are not expected to reopen for multiple hours due to a crash.According to the North Carolina Department of ...
- Aeromexico's US expansion continues with Tampa despite DOT pushback on crucial Delta partnership
Aeromexico said it will start a new daily flight between Tampa and Mexico City, marking its 23rd U.S. city even as the U.S. Department of Transportation is pushing back against its joint venture ...
- Nearly all new DOT codes issued for plants in Asia
WASHINGTON — The U.S. Department of Transportation (DOT) issued 21 new plant identification codes in ... The exception is for Nokian Tyres P.L.C.'s factory under construction in Romania. Nokian ...
- DoT to fund six chip design projects
The DoT, along with C-DOT, is evaluating another 600 proposals as part of TTDF. The Department of Telecommunications (DoT) is looking to fund at least six chip design projects this year under the ...
- D.C. Digest: White House watchdog site gets Lankford's approval
Members of Congress are known more for criticizing government than praising it, particularly when the agency in question is run by the opposition party.